NEW YORK -- Which insiders are selling and buying chunks of stocks?

Below are lists of the top 10 open-market insider purchases and sales filed at the Securities and Exchange Commission Wednesday as ranked by dollar value. Company executives and directors are in the best position to assess the attractiveness of their firms' shares, and here is how many of them are voting their wallets! Please note, however, that these are factual lists, not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction.

For the most up-to-date insider data, and fundamentally researched investment ideas inspired by insiders, check out www.InsiderInsights.com.

Rae Systems (RAE) Kopp Leroy C BO 100,000 $172,000
Sun Bancorp Nj (SNBC) Brown Bernard A CB,DIR,BO 20,000 $89,800
CPEX Pharmaceuticals (CPEX) Black Horse Capital Mgt LLC BO 7,381 $77,290
Legend International (LGDI) Kisan International Trading Fze BO 88,800 $53,280
Community West Bancshares (CWBC) Peeples William R DIR,BO 20,400 $49,160
General American Investors (GAM) Neidich Daniel DIR 2,200 $45,445
Sun Bancorp Nj (SNBC) Brown Sidney R VCB,DIR,
TR,SEC
10,000 $44,800
Tollgrade Communications (TLGD) Ramius LLC BO 7,750 $41,419
Tortoise Power & Energy Infrastructure Fd (TPZ) Matlack Terry CFO,DIR 1,500 $30,000
Allegheny Technologies (ATI) Jeremiah Barabara S DIR 1,000 $27,760
Boston Properties (BXP) Zuckerman Mortimer B CB 299,667 $15,930,298
Boston Properties (BXP) Linde Edward H CEO,DIR 300,000 $15,870,000
Stryker (SYK) Stryker Ronda E DIR 320,000 $12,471,616
Apollo Group (APOL) Sperling John G CB,DIR,BO 150,000 $10,044,930
Salix Pharmaceuticals (SLXP) Flynn James E BO,BO 357,612 $4,649,910
Equity Lifestyle Properties (ELS) Walker Howard VCB,DIR 74,757 $3,055,692
NVR (NVR) Schar Dwight C DIR 4,351 $2,679,868
Berkshire Hathaway (BRK) Bill & Melinda Gates Foundation BO 600 $1,873,484
Dyncorp International (DCP) Mckeon Robert B DIR,BO 90,000 $1,813,200
Somaxon Pharmaceuticals (SOMX) Boxer Capital LLC BO 500,000 $1,550,000

Written by Jonathan Moreland in New York.
Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. While he cannot provide investment advice or recommendations, Moreland appreciates your feedback; click here to send him an email.